| 前收盘价格 | 5.04 |
| 收盘价格 | 5.05 |
| 成交量 | 4,195,832 |
| 平均成交量 (3个月) | 4,343,034 |
| 市值 | 1,700,183,680 |
| 价格/销量 (P/S) | 24.16 |
| 股市价格/股市净资产 (P/B) | 5.06 |
| 52周波幅 | |
| 利润日期 | 4 May 2026 |
| 营业利益率 (TTM) | -1,913.23% |
| 稀释每股收益 (EPS TTM) | -2.20 |
| 总债务/股东权益 (D/E MRQ) | 2.72% |
| 流动比率 (MRQ) | 9.01 |
| 营业现金流 (OCF TTM) | -157.34 M |
| 杠杆自由现金流 (LFCF TTM) | -64.76 M |
| 资产报酬率 (ROA TTM) | -23.33% |
| 股东权益报酬率 (ROE TTM) | -119.66% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Nuvation Bio Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 3.0 |
| 内部交易活动 | -1.5 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -3.5 |
| 平均 | -0.80 |
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 19.14% |
| 机构持股比例 | 62.26% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Decheng Capital Llc | 31 Dec 2025 | 25,954,439 |
| Omega Fund Management, Llc | 31 Dec 2025 | 8,081,089 |
| Laurion Capital Management Lp | 31 Dec 2025 | 7,852,638 |
| Tang Capital Management Llc | 31 Dec 2025 | 3,857,457 |
| Redmile Group, Llc | 31 Dec 2025 | 3,163,256 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 13.00 (RBC Capital, 165.85%) | 购买 |
| 中 | 11.00 (124.95%) | |
| 低 | 7.00 (UBS, 43.15%) | 保留 |
| 平均值 | 10.33 (111.25%) | |
| 总计 | 2 购买, 1 保留 | |
| 平均价格@调整类型 | 4.81 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| RBC Capital | 03 Mar 2026 | 13.00 (165.85%) | 购买 | 4.36 |
| UBS | 03 Mar 2026 | 7.00 (43.15%) | 保留 | 4.36 |
| Wedbush | 10 Feb 2026 | 11.00 (124.95%) | 购买 | 5.71 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| LIU DONGFANG | - | 5.08 | -50,000 | -254,000 |
| WENTWORTH KERRY | - | 5.08 | -36,750 | -186,690 |
| 累积净数量 | -86,750 | |||
| 累积净值 ($) | -440,690 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 5.08 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| LIU DONGFANG | 职员 | 17 Apr 2026 | 自动卖出 (-) | 50,000 | 5.08 | 254,000 |
| LIU DONGFANG | 职员 | 17 Apr 2026 | 执行期权 | 50,000 | - | - |
| WENTWORTH KERRY | 职员 | 17 Apr 2026 | 自动卖出 (-) | 36,750 | 5.08 | 186,690 |
| WENTWORTH KERRY | 职员 | 17 Apr 2026 | 执行期权 | 36,750 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合